Henrietta Lacks and the consent gap in medical research

In January 1951, Henrietta Lacks, a Black woman from Turners Station, Maryland, was treated for cervical cancer at Johns Hopkins Hospital. Without her or her family's knowledge or consent, tissue samples taken during her treatment were cultured. Her cells — the HeLa line — became the first immortal human cell line and the most-used cell line in biomedical research, contributing to the polio vaccine, in vitro fertilization, cancer biology, and the COVID-19 vaccine pipeline.

Lacks died in October 1951. Her family was not informed that her cells had been propagated until the 1970s, when researchers contacted them for genetic samples; the family received no compensation and had no say in subsequent research uses. In 2013, after publication of the HeLa genome, the National Institutes of Health negotiated an agreement giving the family a limited consultative role in HeLa-genome data access decisions.

Rebecca Skloot's ``The Immortal Life of Henrietta Lacks`` (2010) and Dorothy Roberts's ``Killing the Black Body`` (1997) frame the case in the policy register: the structural absence of informed consent for Black patients in 1951 was not an administrative oversight, and the 1979 Belmont Report's three principles (respect for persons, beneficence, justice) are the regulatory remedy still in use.

Henrietta Lacks was a Black American woman who died of cervical cancer at Johns Hopkins Hospital on October 4, 1951. Biopsy samples of her cervical-cancer cells were taken before her death without her knowledge or consent. The samples were transferred to Dr. George Gey's research laboratory, where they established the first successfully cultured immortal human-cell line. The cell line, designated HeLa, has been the foundational laboratory resource for cellular and molecular biology research over the subsequent seven decades. Research using HeLa cells produced the polio vaccine, the first cloning experiments, the chromosomal analyses that established the human chromosome count, large portions of the cancer-research literature, and substantial portions of the HIV and radiation-biology literatures.

Neither Henrietta Lacks nor her surviving family received compensation for the cells or for the research products derived from them. The family did not learn of the existence of the cell line or of its commercial significance until approximately 1973. Rebecca Skloot's 2010 book 'The Immortal Life of Henrietta Lacks' brought the family's experience to broad public attention and produced sustained subsequent institutional attention to the case. The institutional response has included the Johns Hopkins University Henrietta Lacks Foundation, the 2013 NIH-family data-access agreement governing research using HeLa-derived genome data, the 2018 Common Rule revisions addressing biospecimen-consent questions, and several settlements with biotechnology companies that had commercialized HeLa-based products.

The case is treated in the modern bioethics literature as a load-bearing reference on patient consent in biospecimen research. The Tuskegee Syphilis Study, the Guatemala syphilis experiments, the Willowbrook hepatitis studies, and the HeLa-cell-line case constitute the principal twentieth-century American medical-research-ethics reference cases. The cumulative pattern is the use of minority and institutionalized populations as subjects without informed consent, the subsequent use of the research products in ways that produced substantial scientific or commercial value, and the long-delayed institutional acknowledgment of the original ethical failure.

The contemporary biospecimen-research framework, codified in the 2018 Common Rule revision and in successive federal-agency guidance, requires informed consent for biospecimen collection in most contexts and provides for researcher-subject communication on subsequent research uses. The framework is substantially more protective than the 1951 practice that produced the HeLa cell line, but it does not fully resolve the underlying question of how subjects' contributions to research that produces substantial scientific or commercial value should be recognized over the long term. The platform's framing treats the HeLa case as a continuing reference point in the broader question of how the biomedical-research enterprise relates to the populations from which it draws its subjects, particularly minority populations whose historical experience has included repeated instances of uncompensated research extraction.

The contemporary biospecimen-research consent framework operates principally through the 2018 Common Rule revisions, which establish informed-consent requirements for biospecimen collection in research contexts. The revisions modified the previous biospecimen-research framework in ways intended to address the questions the HeLa case had raised about the use of biospecimens in research without specific consent. The modified framework requires consent for collection of biospecimens for research use, provides for researcher-subject communication on subsequent research uses, and establishes additional procedural protections for biospecimen research with potentially identifiable subjects.

The contemporary commercial-genomics framework has produced substantial subsequent ethical engagement on questions structurally similar to those the HeLa case raised. The operational practice of direct-to-consumer genetic-testing companies, the federal AllOfUs precision-medicine program, the National Institutes of Health's All of Us Research Program's data-sharing framework, and the broader commercial and federal genomic-research infrastructure all involve complex consent and benefit-sharing questions that the post-HeLa institutional framework has only partially resolved. The platform's framing treats the HeLa case as a continuing reference point for the operational practice of biomedical-research consent and benefit-sharing rather than as a resolved historical question; the cumulative subsequent engagement with the questions the case raised remains substantially active.